Neuropathic Pain Study With Botulinum Toxin A in Spinal Cord Injury Patients

• Status: Completed
• Trial end date: 2013-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether botulinum toxin A is effective in the treatment of neuropathic pain in spinal cord injury patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Catholic University of Korea Saint Paul's Hospital
• Collaborators: Medy-Tox; National Health Insurance Service Ilsan Hospital
• Treatments: abobotulinumtoxinA; Botulinum Toxins; Botulinum Toxins, Type A; incobotulinumtoxinA; onabotulinumtoxinA

Criteria

Inclusion Criteria:

• more than twenty years of age

• paraplegic or tetraplegic due to cervical and thoracic spinal cord injury

• more than 12 months since spinal cord injury and ASIA impairment scale unchanged for more than 6 months

• persistence of neuropathic pain for more than three months or remission and recurrence of neuropathic pain for more than six months

• a pain score of 40mm or more on the visual analogue scale

Exclusion Criteria:

• neuropathic pain caused by confounding factors other than spinal cord injury

• contraindicated for botulinum toxin type A

• a change in pain medication one month prior to study enrollment

• a condition involving neuromuscular junction (Ex. Eaton Lambert disease, myasthenia gravis)

• person who received botulinum toxin type A within three months prior to study enrollment